3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
17
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
6
Glioblastoma
5
Triple Negative Breast Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Follicular
4
Colorectal Neoplasms
4
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumors
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hereditary Sensory and Autonomic Neuropathies
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Tongue Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Salivary Gland Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pre-menopausal Breast Cancer
1
Interventions
Cyclophosphamide
32
Tacrolimus
29
fludarabine
27
Mycophenolic Acid
23
fludarabine phosphate
22
Busulfan
19
Whole-Body Irradiation
18
Melphalan
16
Methotrexate
15
Antilymphocyte Serum
14
Rituximab
12
Bortezomib
11
Stem Cell Transplantation
10
Cyclosporine
10
thymoglobulin
9
Sirolimus
9
Granulocyte Colony-Stimulating Factor
9
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Interviews as Topic
7
Filgrastim
7
Dexamethasone
7
Clofarabine
7
Blood Specimen Collection
6
Alemtuzumab
6
merphos
5
Voriconazole
5
Standard of Care
5
Nivolumab
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hematologic Neoplasms
×
NVP-BKM120
×
Clear all
NCT01833169
2018-10-19
SIGNATURE
Novartis
Phase 2
Completed
146 enrolled
17 charts